<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">UR</journal-id><journal-title-group><journal-title>Urology Research</journal-title></journal-title-group><issn>3083-4910</issn><eissn>2981-8230</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/ur.v4i2.15360</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Ultra-minimally Invasive Prostatic Urethral Dilation for Small-volume Benign Prostatic Obstruction: A Case Report</title><url>https://artdesignp.com/journal/UR/4/2/10.26689/ur.v4i2.15360</url><author>ShenKun,FuGuangbo,ZhangDawei,YuLeinan</author><pub-date pub-type="publication-year"><year>2026</year></pub-date><volume>4</volume><issue>2</issue><history><date date-type="pub"><published-time>2026-07-07</published-time></date></history><abstract>Background: Small-volume benign prostatic obstruction (BPO) represents a distinct clinical phenotype in which lower urinary tract symptoms (LUTS) are often driven by functional and microenvironmental factors rather than anatomical enlargement. Conventional treatment strategies may be less effective in this subgroup. Case presentation: We report the case of a 66-year-old male with severe LUTS and a small prostate volume (20 mL) who showed inadequate response to medical therapy. The patient underwent prostatic urethral dilation (PUD) using an ultra-minimally invasive prostate dilation catheter (Longevity bar). At 3-month follow-up, improvements were observed in symptom score, urinary flow rate, and post-void residual volume, while sexual function was preserved, and no procedure-related complications occurred. Conclusion: PUD may provide a potential treatment option for selected patients with small-volume BPO. Further studies are needed to determine its long-term efficacy and clinical role.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Roehrborn C, 2005, Benign Prostatic Hyperplasia: An Overview. Reviews in Urology, 7(Suppl 9): S3–S14.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Miernik A, Gratzke C, 2020, Current Treatment for Benign Prostatic Hyperplasia. Deutsches Ärzteblatt International, 117(49): 843–854.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Lerner L B, McVary K, Barry M, et al., 2021, Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Part I—Initial Work-Up and Medical Management. Journal of Urology, 206(4): 806–817.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Xu J, Han B, Xia S, et al., 2025, Beyond Size: A Comprehensive Overview of Small-Volume Benign Prostatic Hyperplasia. Current Urology, 19(1): 1–5.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>De Nunzio C, Presicce F, Tubaro A, 2016, Inflammatory Mediators in the Development and Progression of Benign Prostatic Hyperplasia. Nature Reviews Urology, 13(10): 613–626.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Fibbi B, Penna G, Morelli A, et al., 2010, Chronic Inflammation in the Pathogenesis of Benign Prostatic Hyperplasia. International Journal of Andrology, 33(3): 475–488.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Bushman W, Jerde T, 2016, The Role of Prostate Inflammation and Fibrosis in Lower Urinary Tract Symptoms. American Journal of Physiology-Renal Physiology, 311(4): F817–F821.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Savvides E, Langas G, Sountoulides P, 2024, Editorial for Special Issue: Current and Emerging Therapies for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Journal of Clinical Medicine, 13(9): 2453.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Franco J, Tesolin P, Jung J, 2023, Update on the Management of Benign Prostatic Hyperplasia and the Role of Minimally Invasive Procedures. Prostate International, 11(1): 1–7.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Shen K, Chen C, Yu L, 2025, Dilemmas and Breakthroughs in the Treatment of Benign Prostatic Hyperplasia in China. Modern Health Science, 8(1): 112.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Yoosuf B, Panda A, Kt M, et al., 2024, Comparative Efficacy and Safety of Alpha-Blockers as Monotherapy for Benign Prostatic Hyperplasia: A Systematic Review and Network Meta-Analysis. Scientific Reports, 14(1): 11116.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Plochocki A, King B, 2022, Medical Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 49(2): 231–238.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Couteau N, Duquesne I, Frédéric P, et al., 2021, Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review. Journal of Clinical Medicine, 10(24): 5788.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><p>Elterman D, Aubé-Peterkin M, Evans H, et al., 2022, Update—Canadian Urological Association Guideline: Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. Canadian Urological Association Journal, 16(8): 245–256.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><p>Madersbacher S, Klingler H, Djavan B, et al., 1997, Is Obstruction Predictable by Clinical Evaluation in Patients with Lower Urinary Tract Symptoms? British Journal of Urology, 80(1): 72–77.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><p>Dobrek L, 2023, Lower Urinary Tract Disorders as Adverse Drug Reactions—A Literature Review. Pharmaceuticals, 16(7): 1031.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><p>O’Mahony C, Arshad M, Norton S, 2025, Testosterone and Lower Urinary Tract Symptoms: A Narrative Review. Current Urology Reports, 26(1): 75.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><p>Jennings R, Ganote C, Reimer K, 1975, Ischemic Tissue Injury. American Journal of Pathology, 81(1): 179–198.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><p>Ren J, Li Y, Zhang X, et al., 2024, Correlation Between Metabolic Syndrome and Periurethral Prostatic Fibrosis: Results of a Prospective Study. BMC Urology, 24(1): 38.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><p>Kaltsas A, Kratiras Z, Zachariou A, et al., 2024, Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health. Biomedicines, 12(1): 110.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><p>Kassabian V, 2003, Sexual Function in Patients Treated for Benign Prostatic Hyperplasia. The Lancet, 361(9351): 60–62.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><p>Nollen J, Pijnappel L, Schoones J, et al., 2023, Impact of Early Postoperative Indwelling Urinary Catheter Removal: A Systematic Review. Journal of Clinical Nursing, 32(9–10): 2155–2177.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><p>Abdelmoteleb H, Jefferies E, Drake M, 2016, Assessment and Management of Male Lower Urinary Tract Symptoms (LUTS). International Journal of Surgery, 25: 164–171.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><p>Cash H, Wendler J, Minore A, et al., 2024, Primary Bladder Neck Obstruction in Men—New Perspectives in Physiopathology. Prostate Cancer and Prostatic Diseases, 27(1): 54–57.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><p>Gerard S, Sinclair A, Morley J, et al., 2022, Prostate Diseases. Pathy’s Principles and Practice of Geriatric Medicine, 2: 1136–1152.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><p>Smith C, Chancellor M, 2004, Emerging Role of Botulinum Toxin in the Management of Voiding Dysfunction. Journal of Urology, 171(6): 2128–2137.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><p>Chimenti I, Sattler S, Del Monte-Nieto G, et al., 2022, Editorial: Fibrosis and Inflammation in Tissue Pathophysiology. Frontiers in Physiology, 12: 830683.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><p>Lerner L B, McVary K, Barry M, et al., 2021, Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Part II—Surgical Evaluation and Treatment. Journal of Urology, 206: 818–826.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><p>Nitti V, 2005, Pressure Flow Urodynamic Studies: The Gold Standard for Diagnosing Bladder Outlet Obstruction. Reviews in Urology, 7(Suppl 6): S14–S21.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><p>Blanker M, Brandenbarg P, Slijkhuis B, et al., 2019, Development of an Online Personalized Self-Management Intervention for Men With Uncomplicated LUTS. Neurourology and Urodynamics, 38(6): 1685–1691.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
